How often is xgeva given for bone metastases?

How often is Xgeva given for bone metastases?

Xgeva contains denosumab and is given as a 120 mg subcutaneous injection every four weeks. This schedule applies when treating adults with bone metastases from solid tumors.

Can biosimilars enter before the Xgeva patent expires?

Biosimilars to Xgeva have already launched in the United States. A denosumab biosimilar from Sandoz entered the market in May 2024. The original Xgeva patent expires in 2025.

Why are companies challenging this patent?

Companies challenge the Xgeva patent mainly to launch biosimilars sooner. Challenges include invalidity claims and non-infringement arguments. The timing of these challenges occurs before or after the 2025 expiration date.

What happens if a patient skips a scheduled Xgeva dose?

Skipping a dose may increase the risk of skeletal-related events such as fractures or spinal cord compression. Patients who miss a dose should consult their doctor to reschedule as soon as possible.